Novartis, a leading global medicines company, announced that the US Food and Drug Administration (FDA) approved Beovu (brolucizumab) injection, also known as RTH258 for the treatment of wet age─related macular degeneration (AMD).
Novartis, a leading global medicines company, announced that the US Food and Drug Administration (FDA) approved Beovu (brolucizumab) injection, also known as RTH258 for the treatment of wet age─related macular degeneration (AMD).
Pharmamarketeer richt zich op marketingprofessionals van farmaceuten en andere medisch-gerelateerde organisaties in Nederland en België.
Copyright 2023 © Uitgave van MedHealth Communications BV | Privacy disclaimer
